A unique model
IRIC, located in the heart of the Université de Montréal campus, operates according to a unique model in Canada that combines, under one roof, fundamental research activities, a university-level training program and a research maturation team. These generate discoveries that advance knowledge or that can quickly translate into new therapeutic solutions.
-
![]()
News Guy Sauvageau Named Knight of the Ordre de Montréal
On May 8, Professor Guy Sauvageau, Director of IRIC’s Molecular Genetics of Stem Cells Research Unit, will be presented with the insignia of the Ordre de Montréal as a Knight.
-
![]()
News RIMap-RISC: A New Interface to Study RNA Biology
The team led by François Major, director of IRIC’s RNA Engineering Research Unit, has developed the new RIMap-RISC database, which integrates the molecular structure of microRNAs and messenger RNAs to systematically model their interactions. Led by PhD student Simon Chasles, this work is the subject of a publication in Genome Biology.
-
![]()
News Marc Therrien’s team wins the 2025 Discovery of the Year Award - Québec Science
The team led by Marc Therrien, Principal Investigator and Chief Executive Officer at IRIC, has won Québec Science magazine’s 2025 Discovery of the Year award for its work on the BRAF protein and its role in the spread of cancer cells. The winner was chosen by the public, with more than 2,000 people participating in the vote.
-
![]()
News In Search of New Antibiotics to Counter Antibiotic Resistance
IRIC’s Drug Discovery Unit (DDU) is part of the project “Designing Antibiotics Targeting Klebsiella Using Artificial Intelligence,” which has received US$3.8 million (approximately CA$5.3 million) from the Gates Foundation.
-
![]()
News Meet Simon-Pierre Gravel, new Principal Investigator at IRIC!
IRIC is proud to announce the arrival of Simon-Pierre Gravel as the new Principal Investigator in the Cancer metabolism and signaling Unit. Simon-Pierre Gravel has kindly agreed to answer a few questions
-
![]()
News A model for modern biopharma collaboration — the enduring partnership between Ipsen, IRIC and IRICoR
In an era where breakthrough science increasingly depends on deep, cross sector collaboration, the longstanding partnership between Ipsen and the teams at the Institute for Research in Immunology and Cancer (IRIC) and its commercialization unit, IRICoR, at Université de Montréal stands out as a model for how academia and industry can accelerate science with purpose. First initiated in 2020 and now extended twice, the partnership is now collaborating on four active oncology research programs. Pierre Beaulieu, Associate Director, Drug Discovery Unit at IRIC, Hugo Lavoie, Associate Director of the Intracellular Signalling Research Unit at IRIC, and Chris Hupp, Senior Director, Research & External Innovation at Ipsen, explain how this collaboration has evolved from a promising research alliance into a formidable engine to deliver transformative therapies for patients.
Upcoming events
-
Upcoming May 21, 2026 Gala Audace - IRIC Fundraising Event
Since 2014, IRIC has organized the Audace fundraising event, which contributes annually to funding groundbreaking discoveries in the fight against cancer.
The Audace Gala is much more than just an evening: it’s a moment of sharing, solidarity and hope. Let’s unite our generous hearts to support therapeutic advances through cancer research.
Latest publications
See all publications-
March 26, 2026 Extracellular vesicles from aged individuals trigger mitochondrial dysfunction in haematopoietic progenitor cells.
Grenier-Pleau IJ, Kaur J, Wells CJ, Vermeulen M, Slobodyanyuk M, Holmes SM, Bonneil E, Hall C, Beaulieu J, Hosseini M, Chan SM, Dick SA, Knapp D, Tyryshkin K, Postovit LM, Thibault P, Rudan JF, Mann S, Craig AW, Reimand J, Chan EYW, Abraham SA
Haematologica 2026-03-26 ; - See all publications